ETTX ETTX

Entasis Therapeutics Stock Price

2.19
0.00 (0.0%)
Upgrade to Real-Time
Afterhours (Closed)
2.19
Volume 0
Bid Price 2.21
Ask Price 2.19
News -
Day High

Low
1.40

52 Week Range

High
3.8799

Day Low
Company Name Stock Ticker Symbol Market Type
Entasis Therapeutics Holdings Inc ETTX NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.0% 2.19 20:00:00
Open Price Low Price High Price Close Price Prev Close
2.19 2.19
Trades Volume Avg Volume 52 Week Range
0 0 - 1.40 - 3.8799
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 2.19 USD

Period:

Draw Mode:

Entasis Therapeutics Holdings Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 104.80M 47.85M 18.61M $ - $ - -1.09 -2.00
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - - 4.10%

more financials information »

Entasis Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical ETTX Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.000.000.000.0000.000.0%
1 Month0.000.000.000.0000.000.0%
3 Months1.832.201.782.18375,2050.3619.67%
6 Months1.772.201.622.08170,4520.4223.73%
1 Year2.633.87991.402.45257,431-0.44-16.73%
3 Years6.669.251.402.47246,469-4.47-67.12%
5 Years13.4513.701.402.72198,952-11.26-83.72%

Entasis Therapeutics Description

Entasis Therapeutics Holdings Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. The company's pathogen-targeted design platform has produced a pipeline of product candidates, including SUL-DUR (targeting Acinetobacter baumannii infections), zoliflodacin (targeting Neisseria gonorrhoeae infections), ETX0282CPDP (targeting Enterobacterales infections) and ETX0462 (targeting Gram-negative infections including Pseudomonas).


Your Recent History
NASDAQ
ETTX
Entasis Th..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to InvestorsHub
Register Now